Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7484921 | 0.99 | HRH3 (0.45) | HRH3SLC6A4SLC6A2CYP19A1OPRD1 | |
| SCHEMBL7452182 | 0.84 | OPRD1 (0.50) | HRH3SLC6A4SLC6A2CYP19A1OPRD1 | |
| SCHEMBL5552211 | 0.84 | HRH3 (0.41) | HRH3SLC6A4CYP19A1 | |
| SCHEMBL7156162 | 0.84 | CYP19A1 (0.42) | HRH3CYP19A1 | |
| SCHEMBL7746101 | 0.81 | CYP19A1 (0.43) | HRH3SLC6A4CYP19A1 | |
| SCHEMBL7461734 | 0.79 | HRH3 (0.37) | HRH3CYP19A1USP2 | |
| SCHEMBL7462978 | 0.79 | HRH3 (0.42) | HRH3CYP19A1 | |
| SCHEMBL7855272 | 0.79 | HRH3 (0.38) | HRH3CYP19A1 | |
| SCHEMBL7121496 | 0.79 | HRH3 (0.36) | HRH3CYP19A1 | |
| SCHEMBL7132213 | 0.79 | PDK2 (0.37) | HRH3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1158983-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | ENG WAI-SI (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1165082-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-06-12 | — | — | EP | disclosed |
| EP-1158982-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6376496-B1 | TREATMENT OF CANCER | MERCK & CO., INC. | 2002-04-23 | — | — | US | disclosed |
| US-6358956-B1 | IMIDAZOLYLALKYL-1-PIPERAZINE DERIVATIVES; FARNESYL-PROTEIN AND GERANYLGERANYL TRANSFERASE INHIBITORS; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| US-6355643-B1 | ENZYME INHIBITORS, RAS GENES AND PROTEINS | MERCK & CO., INC. | 2002-03-12 | — | — | US | disclosed |
| EP-1165082-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6335343-B1 | IMIDAZOL-5-YLALKYLPIPERIZINE DERIVATIVES; ANTICARCINOGENIC AGENTS | MERCK & CO., INC. | 2002-01-01 | — | — | US | disclosed |
| EP-1158982-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| EP-1158983-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000052134-A2 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051612-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051611-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072081-A1 | Geranylgeranyl transferase inhibitor screening assay | GGT1, FNTA, GGPS1 | HRH3 4170/4885SLC6A4 2985/4885SLC6A2 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.